PubMed Health⌕ Search

Biomedical subjects

K A Strubler

Publications and source records attributed to K A Strubler.

6 recordsLinked to original sources
PubMed1978

Pancreatic carcinoma treated with high-dose, small-volume irradiation.

Eighteen patients with unresectable ductal adenocarcinoma of the pancreas received definitive, high-dose, small-volume radiation therapy. All patients had at least one laparotomy, at which time a biopsy was obtained, radio-opaque clips were placed to define the extent of the gross tumor, and usually some form of bypass procedure was performed. External-beam irradiation was delivered from a 45-MV betatron to an area encompassing the clipped tumor volume plus a 1 to 2 cm margin. A three-field technique, employing opposed lateral 45-MV photon beams and an anterior "mixed beam" (50% 45-MV photons and 50% 15- to 35-MeV electrons), was used to treat 13 of the patients. The choice of electron energy used for these patients was based on the depth of the posterior margin of the target volume. Five patients were treated by either four-field "box" or three-field, 45-MV photon techniques. Minimum tumor dose was 6300-6700 rads delivered in 180-rad fractions in 7-9 weeks. With the three-field technique, all fields were treated daily; with the four-field technique, two fields were treated daily. The projected survival rate 12 months post idagnosis is 59%, with the median length of survival, 11.8 months. Seven patients are alive 11.5 to 57 months after diagnosis, all clinically free of disease. Treatment has been generally well tolerated, and there have been no severe late radiation complications. This therapeutic modality appears capable of producing improved palliation, if not offering definitive radiotherapeutic management of localized unresectable carcinoma of the pancreas.

Adenocarcinoma↗
PubMed1978

Betatron therapy for unresectable pancreatic cancer. A preliminary report.

Nineteen-patients with unresectable but localized ductal adenocarcinoma of the pancreas were treated with definitive high dose, small volume, external beam radiotherapy with promising results. The tumors of all patients were histologically confirmed. A 45 MV betatron was used for radiation of the clipped tumor volume plus a 1 to 2 cm margin. Fourteen patients were treated by a three-field technic with the use of opposed lateral photon beams and an anterior mixed photon-electron beam. Five patients were treated with either a four-field "box" or a three-field photon technic. Tumor doses of 5,900 to 6,700 r were delivered over seven to nine weeks. The twelve month survival rate after diagnosis is 53%. This compares favorably with published reports of patients treated surgically for cure. Four patients are alive 18.5 to 64 months after diagnosis. Three are clinically free of disease. Treatment has been well tolerated and there have been no significant radiation complications.

Adenocarcinoma↗
PubMedDate not supplied

Absorbed dose determination for interstitial 125I boost therapy.

Iodine-125 implants are being used to boost external beam treatments of unresectable pancreas and lung tumors. Calculations of the 125I activity required to achieve a specific average peripheral dose are presented as a function of the average tumor dimension for spherical, ellipsoidal, and cylindrical implants. Both uniform and random seed spacings are investigated. The results indicate that the average peripheral dose is relatively insensitive to the seed distribution as well as to the seed activity. The average tumor dose is typically 20% greater than the average peripheral dose.

Brachytherapy↗